Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) announced that on October 15, 2025 its Compensation Committee granted inducement awards to 20 newly hired employees under the Vor Biopharma 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards comprise 113,478 stock options and 24,319 RSUs. Options have a 10-year term with an exercise price of $30.22 (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months). RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to the Inducement Plan and individual award agreements.

BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 113,478 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 24,319 shares of Vor Bio’s common stock to 20 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).        

The stock options have a ten-year term, and the exercise price is $30.22 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

FAQ

What inducement grants did Vor Bio (VOR) announce on October 31, 2025?

Vor Bio disclosed grants of 113,478 stock options and 24,319 RSUs to 20 newly hired employees, dated October 15, 2025.

What is the exercise price and term of the VOR stock options granted October 15, 2025?

The options carry an exercise price of $30.22 per share and a 10-year term from the grant date.

How do the Vor Bio (VOR) options and RSUs vest for the October 15, 2025 grants?

Both awards vest over four years: 25% after 12 months; options vest monthly thereafter over 36 months and RSUs vest quarterly over the same period.

Under which plan were the VOR inducement awards granted?

The awards were granted under the Vor Biopharma 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Do the October 15, 2025 VOR grants require continued employment to vest?

Yes; vesting of both the options and RSUs is subject to continued employment on the applicable vesting dates.